Quantcast
Search Daily Dose & Film Annex
Loading

BIO SmartBrief

Daily Dose Newsletter

See all Access Pharmaceuticals articles @ Daily Dose

Access Pharmaceuticals, Inc. (OTCBB: ACCP) is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation platinum chemotherapeutic drug and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.